Press Page

Welcome to the official press page of Sanity Group!
All relevant contents for media representatives in one place.

Press Contact

For all kinds of media inquiries

Jennifer Plankenbuehler

Lead Medical PR| Press Officer

Email: jennifer.plankenbuhler@sanitygroup.com | presse@sanitygroup.com

Phone: +49 173 37 62 845

For marketing/advertising or any other inquiries please contact: info@sanitygroup.com

Sanity Group GmbH
Jägerstraße 28-31 | 10117 Berlin | Germany

Contact for all kinds of media inquiries

Ms Jennifer Plankenbuehler

Press Spokesperson | Lead Medical PR 

Email: jennifer.plankenbuhler@sanitygroup.com | presse@sanitygroup.com

Phone: +49 173 37 62 845

For marketing/advertising or any other inquiries please contact: info@sanitygroup.com

Our
Headquarter

Sanity Group GmbH | Jägerstr. 28-31 | 10117 Berlin | Germany

About Sanity Group

The Berlin-based health and life science company Sanity Group aims to improve people’s quality of life through the use of cannabinoids and the utilization of the endocannabinoid system. The focus is on pharmaceuticals (medical cannabis; finished pharmaceuticals) on the one hand, and cannabinoid-based consumer goods as well as scientific research on recreational cannabis on the other. Sanity Group, founded in Berlin in 2018 by Finn Age Hänsel and Fabian Friede, is supported financially and strategically by investors such as Casa Verde Capital (Snoop Dogg), Navy Capital, Redalpine, HV Capital, Calyx, Cherry Ventures, Bitburger Ventures, SOJE Capital, and various business angels and celebrities such as Will.i.am (Black Eyed Peas), Scooter Braun, Hollywood actor Alyssa Milano and German soccer player Mario Götze.

The Berlin-based health and life science company Sanity Group aims to improve people’s quality of life through the use of cannabinoids and the utilization of the endocannabinoid system. The focus is on pharmaceuticals (medical cannabis; finished pharmaceuticals) and medical products on the one hand, and cannabinoid-based consumer goods as well as scientific research on the other.

Sanity Group, founded in Berlin in 2018 by Finn Age Hänsel and Fabian Friede, is supported financially and strategically by investors such as Casa Verde Capital (Snoop Dogg), Navy Capital, Redalpine, HV Capital, Calyx, Cherry Ventures, Bitburger Ventures, SOJE Capital, and various business angels and celebrities such as Will.i.am (Black Eyed Peas), Scooter Braun, Hollywood actor Alyssa Milano and German soccer player Mario Götze.

What we do:

Medical & Pharmaceutical

Sanity Group’s medical business, including medical cannabis brands Vayamed, avaay Medical and ZOIKS as well as Endosane Pharmaceuticals (finished pharmaceuticals).

Logistics & Processing

Near Frankfurt am Main, Germany, Sanity Group operates a medical cannabis logistics and processing facility with laboratory.

 

Consumer Health & Science

Sanity Group’s consumer business with the brands vaay (wellbeing) and Grashaus Projects (scientific pilot study on recreational cannabis in Switzerland).  

2018

Sanity Group was founded by Finn Hänsel (CEO) and Fabian Friede (now works as a consultant)

Berlin

is the location of our headquarter; our logistics & processing facility is located near Frankfurt am Main 

100+ Mio $

Total investment (after Series B funding round); Europe’s best-funded cannabis company

85+

Employees from over 15 different nations

50/50

Balanced gender ratio in the team

34,2 y

ø Average age of all employees

“Unfortunately, Cannabis still has very often a negative stigma attached to it. We want to give the plant a new chance, because what people associate with it is based on old prejudices. It’s important to us to actively contribute to education and knowledge transfer. This also involves showing decision-makers the differences between cannabis as a medicine, agricultural substance and lifestyle product. It’s important to understand the full potential of the plant – that’s what we’re working for, to bring cannabis back to the center of European society.”

– Finn Hänsel
Founder & Managing Director, Sanity Group

Downloads & Pictures

Press Pictures & Logo | Media Kit 

Media Center:
Pictures & Logo

Download portraits of our founders & management and press images in high-res and web optimized resolution.

Media Kit

All information about Sanity Group in our digital press kit (PDF).

 

Latest News

Sanity Group Becomes Part of Canadian Cannabis Market Leader Organigram Global to Drive International Growth

  • Germany’s leading medical cannabis company, Sanity Group has entered strategic agreement with longtime investor and partner, Organigram Global Inc.
  • Transaction valuation: Sanity Group has been valued at a total of up to EUR 250 million, consisting of an upfront EUR 130 million and up to EUR 120 million linked to defined performance metrics for twelve months ending March 31, 2027
  • This catalyzes Sanity Group’s long term international growth and international expansion across the European cannabis market

As one of Germany’s leading companies in the medical cannabis sector, Sanity Group has entered into an agreement on a strategic transaction with its long-standing investor and production partner, Organigram Global Inc. (“Organigram”). Based on two highly complementary business models, the two companies are pursuing an integrated approach that prioritizes global growth, diversification of the product portfolio, and, in turn, a sustainable improvement in the supply of cannabis patients. The publicly listed Toronto-headquartered company Organigram [1] contributes extensive expertise in quality-assured cultivation, processing and innovative cannabis product development to the partnership—complementing Sanity Group’s capabilities and experience to create a strong foundation for long-term growth and international expansion across the European cannabis market. Sanity Group will continue to focus on the pharmaceutical segment, confirms founder and CEO Finn Hänsel: “Building on our complementary strengths and synergies, we and Organigram plan not only to sustainably secure the supply of cannabis for patients in Europe, but to strengthen it over the long term. Our focus on distributing medical cannabis to pharmacies, as well as on scientific research and innovation, therefore remains unchanged.”

Read more

Two Years of Legal Cannabis from Specialized Retail Stores: Swiss Pilot Project Shows Positive Effects on Health Protection, Consumer Competence, and Combating the Illicit Market

For more than two years, the scientific pilot project “Grashaus Projects” has been underway in the Swiss canton of Basel-Landschaft. The study examines the regulated, legal sale of recreational cannabis to registered participants through licensed specialty stores, operating under clear legal requirements and providing individualized professional counseling. Implemented operationally by the Sanity Group under the scientific leadership of the Swiss Research Institute for Public Health and Addiction (ISGF), the project is now delivering robust, up-to-date data on how controlled access to recreational cannabis can function in practice. The central findings: legal specialty stores can help push back the illicit market, strengthen consumer competence, and promote harm-reducing behavior – factors that are highly relevant both for Switzerland’s ongoing legislative process on cannabis legalization and for Germany.

Read more

Research application initially rejected: Scientific pilot project on recreational cannabis in Frankfurt and Hanover denied regulatory approval

The Federal Office for Agriculture and Food (BLE) has rejected the research application submitted in December 2024 for the implementation of a pilot project on controlled sale of recreational cannabis in Frankfurt am Main and Hanover. As early as October 2024, the two cities, together with additional project partners, had announced their intention to launch a scientifically monitored project to test the legal distribution of THC-containing products through specialized retail stores. The concept design and operational implementation were to be managed by the Berlin-based cannabis company Sanity Group, which has been operating retail stores since December 2023 as part of a comparable pilot study in the Swiss canton of Basel-Landschaft. As central reason for rejecting the application for Hanover and Frankfurt, the authority stated that the scope of the research clause (§ 2 para. 4) of the Cannabis Consumption Act (KCanG) did not apply. According to the BLE, the project essentially constituted a model project of the so-called “Pillar 2.” The applicants, however, do not accept this reasoning – not least on the basis of a current legal report. An official objection to the rejection has already been filed; in addition, Sanity Group reserves the right to consider further legal action should the objection be dismissed.

Read more

Coalition Agreement Presented: Sanity Group Welcomes Planned Evaluation of Cannabis Law and Calls for Scientific Pilot Projects

The coalition agreement presented today by CDU/CSU and SPD includes an important announcement for the German cannabis industry: The new government plans an unbiased evaluation of the Cannabis Act in autumn 2025, which came into force in April 2024. The aim is to review the current state of the regulated handling of cannabis and, if necessary, make adjustments. Berlin-based cannabis company Sanity Group welcomes this step – and simultaneously calls for the timely approval of scientific pilot projects for the regulated distribution of recreational cannabis.

Read more

Sanity Group in the media

Interesting articles:

Subscribe to press releases

We are happy to provide journalists, bloggers and media representatives with relevant information about Sanity Group on a regular basis. Subscribe to our press distribution list to receive our press releases directly in the future.

We would also be pleased if you keep us informed about publications and send us a specimen copy (gladly as a PDF) to presse@sanitygroup.com. Thank you very much!

Sanity Group signs Strategic Transaction with Organigram
NEWS

Sanity Group has entered into a strategic transaction agreement to become part of Organigram Global, our longstanding investor.

This transaction brings together two highly complementary businesses: Sanity Group’s Europe-focused platform, brands, and market expertise with Organigram’s scale and strong cultivation and R&D capabilities. Together, we aim to build a stronger platform for international growth in regulated cannabis markets.

Organigram Global Logo